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Abstract (unstructured) 
 
The episodic nature of Raynaud’s phenomenon (RP) in systemic sclerosis (SSc) has led to a reliance 
on patient-reported outcome (PRO) instruments such as the Raynaud’s Condition Score (RCS) diary. 
Little is known about the utilisation in routine clinical practice and health professional attitudes 
towards existing PRO instruments for assessing SSc-RP. Members of the Scleroderma Clinical Trials 
Consortium Vascular Working Group (SCTC-VWG, n=28) were invited to participate in a survey 
gauging attitudes towards the RCS diary and the perceived need for novel PRO instruments for 
assessing SSc-RP. Nineteen SCTC-VWG members (68% response rate) from academic units based 
in North America (n=9), Europe (n=8), South America (n=1) and Australasia (n=1) took part in the 
survey. There was broad consensus that RCS diary returns could be influenced by factors including 
seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of RP, 
habituation to RP symptoms, evolution of RP symptom characteristics with progressive obliterative 
microangiopathy, patient coping strategies, respondent burden and placebo effect. There was 
consensus that limitations of the RCS diary might be a barrier to drug development (79% of 
respondents agree/strongly agree) and that a novel PRO instrument for assessing SSc-RP should be 
developed with the input of both clinicians and patients (84% agree/strongly agree).  Perceived 
potential limitations of the RCS diary have been identified along with concerns that such factors might 
impede drug development programs for SSc-RP. There is support within the systemic sclerosis 
community for the development of a novel PRO instrument for assessing SSc-RP. 
 
Abstract word count: 247 
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Raynaud’s phenomenon (RP) describes excessive vasoconstriction of the digital vessels in response 
to cold exposure and/or emotional stress and is a major source of morbidity in systemic sclerosis 
(SSc). A large patient survey ranked RP highest in the overall frequency and impact of disease-
specific symptoms experienced by SSc patients (1). Due to its episodic nature and subjectivity 
surrounding the severity of symptoms, the assessment of RP is challenging and largely reliant upon 
patient reported outcome (PRO) instruments. The Raynaud’s Condition Score (RCS) diary (that 
assesses the frequency, duration and severity/impact of RP) and the RP visual analogue scale (VAS) 
from the Scleroderma Health Assessment Questionnaire (SHAQ) were each developed in the 1990’s 
and are both included in the proposed core set of response measures for clinical trials in SSc (2-5). 
These tools were developed primarily for clinical trials and little is known about the utilization of these 
instruments to evaluate the efficacy of treatments for SSc-RP in routine clinical practice. Recent 
research conducted in Europe and Canada has examined the frequency and choice of vasoactive 
medications in SSc-RP, but has not reported analyses of the comparative efficacy of different 
interventions in routine clinical practice because data was not available (6, 7). One explanation for 
this might be low utilization of PRO instruments to assess SSc-RP in routine clinical practice; possibly 
owing to clinician attitudes towards these tools, difficulties in interpretation, and/or respondent 
burden. We undertook a survey of clinicians with expertise in SSc from within the Scleroderma 
Clinical Trials Consortium (SCTC) Vascular Working Group (VWG) to evaluate the utilization of 
existing PRO instruments for assessing SSc-RP in routine clinical practice and to gauge expert’s 
attitudes on (a) factors influencing outcomes using existing tools and (b) the possible need to develop 
novel instruments for assessing SSc-RP.   
 
Methods 
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The SCTC-VWG is an international group of SSc experts with a focus on the assessment and 
management of peripheral vascular manifestations of SSc. The objectives of the SUbjective 
Raynaud’s Phenomenon Assessment in Systemic Sclerosis (SURPASS)  survey were to evaluate the 
utilization of existing PRO instruments for SSc-RP in routine clinical practice, critically appraise 
potential factors influencing outcomes using existing tools and gauge opinion regarding the need for 
novel PRO instruments for assessing SSc-RP. The SURPASS questionnaire was developed in an 
electronic format and circulated amongst SCTC-VWG members (n=28). Participation in the survey 
was promoted at a face-to-face SCTC-VWG meeting (ACR 2015) and working-group members 
received up to 2 reminder emails (November-December 2015). All respondents provided consent to 
participate. The UK Heath Research Authority confirmed formal ethics approval was not required for 
this work. The survey was reviewed and approved for dissemination by the Research & Development 
directorate of the Royal United Hospitals, Bath. 
  
Results 
 
Nineteen SCTC-VWG members (68% response rate) completed the survey. All were practicing 
rheumatologists with an established interest in SSc (79% seeing >15 patients with SSc per month) 
affiliated with academic units based in North America (n=9), Europe (n=8), South America (n=1) and 
Australasia (n=1). The majority of respondents (95%) had participated in clinical trials of SSc and had 
prior experience of SSc-RP endpoints (83% of respondents).  
 
Most respondents (95%) enquire about RP symptom severity at most/all clinic assessments. All 
respondents are familiar with the SHAQ RP VAS subscale but the majority (53%) had only used this 
in the research/clinical trial setting. Fewer than half of respondents (42%) use the SHAQ RP VAS in 
routine clinical practice; only one of whom (5%) collects this outcome measure at every visit. 
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Utilization of the RCS diary is low; 33% have never used the instrument, 58% in a research/clinical 
trial setting and only 11% report using the RCS diary in clinical practice. There were mixed views 
from respondents regarding the extent to which the RCS diary captures its intended conceptual 
framework (Table 1.). There was consensus that the RCS diary returns are likely influenced by 
seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of RP, 
habituation to RP symptoms, change in RP symptom characteristics with evolution of peripheral 
obliterative microangiopathy, patient coping strategies, respondent burden and placebo effect (Table 
1.). There was consensus that the limitations of the RCS diary might be a barrier to drug 
development (79% of respondents agree/strongly agree), that a novel PRO instrument for SSc-RP 
might aid drug development for SSc-RP (95% agree/strongly agree) and that development of a novel 
PRO instrument for SSc-RP should have combined input of clinicians and patients (84% 
agree/strongly agree).  
 
Discussion 
Existing PRO instruments for SSc-RP were primarily developed for clinical trials and this survey 
indicates they have not been adopted in routine clinical practice to guide treatment decisions for SSc-
RP. Our survey design did not allow us to explore the reasons for the relatively limited use of 
instruments such as the SHAQ and RCS diary in routine clinical practice and this could form the 
focus of additional work. Possible explanations might include limited perceived need for quantification 
of clinical outcomes to guide treatment decisions in SSc and the lack of accepted “treat-to-target” 
approaches to management. Mistrust in the instrument, patient burden and resource implications 
surrounding administering and scoring the RCS diary could be factors limiting its use in routine 
clinical practice. In other diseases, the adoption of outcome measures developed for clinical trials into 
routine clinical practice (e.g. the DAS-28 informing “treat-to-target” approaches in rheumatoid 
arthritis) has improved outcomes (8, 9). A similar approach to routinely capturing information on SSc-
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RP is desirable and might facilitate the collection of “practice-based evidence” to support future 
guideline development (10). The survey has identified attitudes towards existing PRO instruments for 
SSc-RP that might have influenced their use in routine clinical practice such as respondent burden. 
The survey has also captured opinions regarding a number of other factors that might influence RCS 
diary returns (including both factors that directly influence RP symptoms and also factors that might 
influence the reporting of RP symptoms in SSc). The potential influence of these different factors 
identified in this study on RCS diary returns requires further evaluation in prospective studies of SSc 
patients. The chief limitations of this work are the relatively small survey size and selection bias 
having targeted SCTC-VWG members. Nevertheless, the SCTC-VWG benefits from its composition 
of highly experienced clinicians affiliated to major SSc units across four continents. A broader survey 
of general rheumatologists would likely reveal lower utilization of SSc-RP PRO instruments and 
attitudes towards existing instruments could potentially be influenced by lesser experience with these 
tools. Nonetheless, these are significant limitations that have influenced the generalizability of our 
findings. Several potential limitations of existing PRO instruments for assessing SSc-RP have been 
highlighted and there is recognition that these factors might impede drug development programs in 
SSc-RP. A consensus has emerged that work towards a novel PRO for SSc-RP (developed with 
input from SSc clinicians and patients) is needed. A novel PRO instrument for SSc-RP that could be 
administered and scored easily (avoiding the need for diary monitoring if possible), and that could be 
applied in both clinical trials and used to guide routine clinical management decisions for SSc-RP 
would be desirable. 
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 Existing PRO instruments are not routinely used to inform management of SSc-RP 
 Limitations of existing PRO instruments for SSc-RP might be a barrier to drug development 
 There is a need to  develop novel PRO instruments for assessing SSc-RP 
 Greater implementation of PROs into routine clinical practice could facilitate the emergence of 
valuable practice-based evidence for the management of SSc-RP 
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Table 1. Summary of SURPASS survey responses.  
The number indicates the number of respondents (%). The most common response for each item is highlighted in bold. RP, 
Raynaud’s phenomenon; RCS, Raynaud’s Condition Score; PRO, patient-reported outcome; SSc, systemic sclerosis 
 
 Extent to which respondents (n, %) agreed with each statement: 
Unable to 
offer 
opinion 
 
Strongly 
disagree 
Disagree Neither 
disagree or 
agree 
Agree Strongly 
agree 
The RCS 
diary 
accurately 
reflects: 
Frequency of RP 
attacks 
1 (5) 
 
1 (5) 2 (11) 6 (32) 8 (42) 1 (5) 
Duration of RP attacks 1 (5) 
 
1 (5) 3 (16) 8 (42) 5 (26) 1 (5) 
Overall severity and 
impact of RP 
1 (5) 
 
1 (5) 2 (11) 6 (32) 7 (37) 2 (11) 
The RCS 
diary returns 
are 
influenced 
by: 
Difficulty recognizing 
attacks of RP 
0 (0) 
 
0 (0) 7 (37) 2 (11) 7 (37) 3 (16) 
Seasonal variation in 
weather 
1 (5) 
 
0 (0) 0 (0) 0 (0) 9 (47) 9 (47) 
Efforts made to avoid 
attacks of RP 
1 (5) 
 
0 (0) 0 (0) 3 (16) 10 (53) 5 (26) 
Efforts made to 
ameliorate attacks of 
RP 
1 (5) 
 
0 (0) 1 (5) 3 (16) 11 (58) 3 (16) 
Habituation to RP 
symptoms over time 
1 (5) 
 
0 (0) 0 (0) 0 (0) 12 (63) 6 (32) 
Evolution of 
morphological digital 
microvascular disease 
1 (5) 
 
0 (0) 1 (5) 4 (21) 9 (47) 4 (21) 
Patient coping 
strategies 
1 (5) 
 
0 (0) 0 (0) 1 (5) 13 (69) 4 (21) 
Excessive respondent 
burden 
1 (5) 
 
0 (0) 1 (5) 2 (11) 9 (47) 6 (32) 
Placebo effect 2 (11) 
 
0 (0) 1 (5) 2 (11) 8 (42) 6 (32) 
The RCS 
diary:  
Might impede drug 
development in SSc-
RP 
2 (11) 0 (0) 2 (11) 
 
0 (0) 9 (47) 6 (32) 
Is satisfactory and no 
further research is 
required in this area 
0 (0) 7 (37) 10 (53) 1 (5) 0 (0) 1 (5) 
A novel PRO 
instrument 
for SSc-RP: 
Might aid drug 
development in SSc-
RP 
0 (0) 0 (0) 0 (0) 1 (5) 11 (58) 7 (37) 
Should be primarily 
PATIENT-derived 
0 (0) 0 (0) 1 (5)  3 (16) 9 (47) 6 (32) 
Should be primarily 
CLINICIAN-derived 
0 (0) 0 (0) 9 (47) 8 (42) 2 (11) 0 (0) 
Should be CLINICIAN 
and PATIENT-derived  
0 (0) 
 
0 (0) 1 (5) 2 (11) 7 (37) 9 (47) 
  
 
 
 
 
